Physician profile
David Solberg
NPI 1063415479
$1,826.15
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $632 · 2021: $412 · 2022: $170 · 2023: $135 · 2024: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.76 | 2019-2022 | |
| Renovia INC | $368.27 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.36 | 2019-2024 | |
| Daiichi Sankyo INC. | $111.92 | 2019-2020 | |
| Aspira Women'S Health INC | $105.76 | 2021-2022 | |
| Astellas Pharma US INC | $104.47 | 2019-2024 | Veozah |
| Mayne Pharma Commercial LLC | $67.24 | 2021-2024 | |
| Therapeuticsmd, INC. | $55.83 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $47.52 | 2024 | Gemtesa, Myfembree |
| Exeltis, USA INC. | $43.87 | 2021-2023 | Slynd |
| Axonics, INC. | $43.11 | 2023 | Axonics |
| Channel Medsystems, INC. | $40.63 | 2023 | |
| Allergan, INC. | $39.56 | 2019 | |
| Merck Sharp & Dohme LLC | $34.35 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $29.54 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $24.06 | 2019 | |
| Duchesnay USA Incorporated | $23.64 | 2019 | |
| Smith+Nephew, INC. | $17.61 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.54 | 2022 | |
| Hologic Sales and Service, LLC | $15.01 | 2021 | |
| Sanofi Pasteur INC. | $14.78 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.17 | 2019 | |
| Organon LLC | $13.15 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Solberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.